首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1935376

嬰兒痙攣症治療市場按產品類型、給藥途徑和地區分類

Infantile Spasm Treatment Market, By Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版日期: 2026年01月28日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，嬰兒痙攣症治療市場價值將達到 10.8 億美元，到 2033 年將達到 16.7 億美元，2026 年至 2033 年的複合年成長率為 4.1%。

報告內容		報告詳情
基準年：	2025	2026年市場規模：	10.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	4.10%	預計2033年價值：	16.7億美元

嬰兒痙攣症是一種罕見疾病，表現為1歲以下嬰兒的癲癇發作。嬰兒痙攣症會導致腿部或手臂突然抽搐，或頭部快速前傾。痙攣永續數秒。治療嬰兒痙攣症的主要藥物是促腎上腺皮質激素（ACTH），但由於其副作用，醫生也可能選擇抗驚厥藥物，例如Vigabatrin或其他類固醇療法。

市場動態

隨著中樞神經系統感染疾病的日益普遍，嬰兒痙攣症的病例數量也在增加，預計這將有助於嬰兒痙攣症治療市場的擴張。根據美國國家生物技術資訊中心（NCBI）的數據，截至2018年1月，嬰兒痙攣症的發生率為每10,000例活產嬰兒中有2至3.5例。

政府對罕見疾病治療的扶持措施預計將推動市場成長。例如，美國小兒科會與兒童神經病學會、兒童神經病基金會和美國急診醫師學會等合作夥伴攜手，進行宣傳計劃工作，找出認知差距，並拓展推廣管道。

嬰兒痙攣症的復發是推動嬰兒痙攣症治療市場發展的主要因素。岡山大學醫院的研究人員發現，接受促腎上腺皮質激素（ACTH）治療11至37天后，41%的研究對象病情復發。

此外，巴西政府於 2017 年修訂了有關罕見疾病藥物核准的監管規則。 2017 年 12 月，巴西監管機構國家衛生監督局 (ANVISA) 發布了 RDC 205/2017 號決議，其中規定了用於治療、預防或診斷罕見疾病（例如嬰兒痙攣症）的藥物的臨床試驗、註冊和良好生產規範 (GMP) 認證的特殊程序。

本次調查的主要特點

本報告對嬰兒痙攣症治療市場進行了詳細分析，並以 2017 年為基準年，給出了預測期（2018-2026 年）內的市場規模和復合年成長率。
它還重點介紹了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數介紹了全球嬰兒痙攣症治療市場主要企業的概況：公司概況、財務表現、產品系列、市場地位、分銷策略、主要發展、策略和未來計劃。
本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、技術升級、市場擴張和行銷策略做出明智的決策。
這份全球嬰兒痙攣症治療市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員將能夠透過用於分析嬰兒痙攣症治療市場的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第7章競爭情勢

熱圖分析
市佔率分析（3x3矩陣）
公司簡介
- H. Lundbeck A/S
- Mallinckrodt Pharmaceuticals
- Catalyst Pharmaceuticals
- GW Pharmaceuticals plc
- Retrophin, Inc.
- Valerion Therapeutics
- Orphelia Pharma SA
- Insys Therapeutics, Inc.
- Anavex Life Sciences Corp.

第8章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第9章各節

參考
調查方法

簡介目錄

Product Code: CMI2453

Infantile Spasm Treatment Market is estimated to be valued at USD 1.08 Bn in 2026 and is expected to reach USD 1.67 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.08 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.10%	2033 Value Projection:	USD 1.67 Bn

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies.

Market Dynamics

Increasing prevalence of central nervous system infection, may develop infantile spasm which in turn is expected to boost the infantile spasm treatment market. According to the National Center for Biotechnology Information (NCBI), in January 2018, the prevalence of infantile spasm was 2 to 3.5 infants per 10,000 live births.

Government initiatives for rare disease treatment is expected to boost the market growth. For instance, The American Academy of Pediatrics also works with the Child Neurology Society, Child Neurology Foundation, American College of Emergency Physicians, and other partners to build advocacy, identify awareness gaps, and expand outreach opportunities.

The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study.

Moreover, the government of Brazil in year 2017 amended its regulatory rules for approving drugs for rare disease. In December 2017, Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) published Resolution RDC 205/2017, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm.

Key features of the study

This report provides in-depth analysis of the infantile spasm treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global infantile spasm treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global infantile spasm treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the infantile spasm treatment market

Market Segmentation

By Product Type
- Adrenocorticotropic Hormone
- Vigabatrin
- Phase III
By Route of Administration
- Oral
- Parenteral
By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Lundbeck A/S
- Mallinckrodt Pharmaceuticals
- Catalyst Pharmaceuticals
- GW Pharmaceuticals plc
- Retrophin, Inc.
- Valerion Therapeutics
- Orphelia Pharma SA
- Insys Therapeutics, Inc.
- Anavex Life Sciences Corp.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Route of Administration
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend

4. Global Infantile Spasm Treatment Market , By Product Type, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adrenocorticotropic Hormone
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Vigabatrin
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Phase III
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Infantile Spasm Treatment Market , By Route of Administration, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Parenteral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Infantile Spasm Treatment Market , By Region, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- H. Lundbeck A/S
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Mallinckrodt Pharmaceuticals
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Catalyst Pharmaceuticals
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- GW Pharmaceuticals plc
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Retrophin, Inc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Valerion Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Orphelia Pharma SA
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Insys Therapeutics, Inc.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Anavex Life Sciences Corp.
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates

8. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

嬰兒癲癇治療市場－全球產業規模、佔有率、趨勢、機會、預測：依治療層級、藥物類型、劑量、地區和競爭格局分類，2021-2031年

嬰兒痙攣症藥物市場規模、佔有率和成長分析（按療法、類型、劑量、給藥途徑、最終用戶、分銷管道和地區分類）—2026-2033年產業預測

嬰兒痙攣症治療市場－全球產業規模、佔有率、趨勢、機會和預測，依治療類別、藥物類型（氨己烯酸、促腎上腺皮質激素、其他）、劑量、地區和競爭格局分類，2020-2030年預測

嬰兒痙攣症藥物市場（依治療層級、通路和給藥途徑）－全球預測 2025-2032

2025-2033年嬰兒痙攣治療市場依治療類別、藥物類型（氨己烯酸、促腎上腺皮質激素等）、劑量、給藥途徑、配銷通路、最終用戶和地區

FAQ

嬰兒痙攣症治療市場按產品類型、給藥途徑和地區分類

Infantile Spasm Treatment Market, By Product Type (Adrenocorticotropic Hormone, Vigabatrin, and Phase III), By Route of Administration (Oral and Parenteral), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

市場動態